Published on Medical Design Technology (http://www.mdtmag.com)

Home > Avedro lands second FDA orphan drug status

Avedro lands second FDA orphan drug status

Mass High Tech: The Journal of New England Technology

The U.S. Food and Drug Administration has granted a second orphan drug designation to Waltham ophthalmologic device and pharmaceutical developer Avedro Inc. for a treatment of corneal ectasia. The designation relates to VibeX, its riboflavin solution intended for use with UVA irradiation, the KXL system for Corneal Cross-linking, which the company said on its website helps strengthen the cornea following refractive surgery.

SOURCE [1]

Source URL (retrieved on 06/19/2013 - 4:12pm): http://www.mdtmag.com/news/2011/12/avedro-lands-second-fda-orphan-drug-status

Links:
[1] http://www.masshightech.com/stories/2011/12/05/daily25-Avedro-lands-second-FDA-orphan-drug-status.html